A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients "IMPALA"

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients "IMPALA"

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 May 2018

At a glance

  • Drugs Molgramostim (Primary)
  • Indications Pulmonary alveolar proteinosis
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPALA
  • Sponsors Savara Pharmaceuticals; Serendex Pharmaceuticals
  • Most Recent Events

    • 09 May 2018 According to a Savara Pharmaceuticals media release, enrollment was at 96 patients at the end of Q1 and complete enrollment is expected in Q3 2018.
    • 11 Apr 2018 Planned End Date changed from 1 Apr 2019 to 1 Sep 2019.
    • 11 Apr 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top